The Polish pharmaceutical market: how major drugmakers view it

The Polish pharmaceutical market has grown dynamically in the past five years, showing great resilience to the impact of adverse trends prevailing in the market. As demonstrated by the results of the most recent study conducted by the advisory company KPMG and the Poland-based research company PMR in June 2009, the current economic situation linked to the global economic crisis has not affected the good performance of the pharmaceutical industry; either, it has not had an adverse effect on the optimistic mood prevailing among pharmaceutical companies in Poland.

Marcin Rudnicki, partner and dead of the Pharmaceuticals Group at KPMG believes that 'pharmaceutical companies expect continued growth of the market. Over half of companies surveyed plan to increase investments in employee development and production infrastructure in the next 12 months.' He also points out that 'more than 60% of the surveyed companies described the current market situation as good or very good - a steep 40% of the surveyed companies plan to introduce three to 10 new drugs by the end of 2009.'